Disease-modifying treatments in transthyretin amyloid cardiomyopathy: a meta-analysis of randomized controlled trials

30 August 2024 (12:00 - 12:50)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Doctor Cheng-Hsuan Tsai

National Taiwan University Hospital, Taipei (Taiwan)

8 More presentations in this session

Presentation thumbnail

Effects of Sacubitril/Valsartan on all-cause hospitalizations in heart failure: participant-level pooled analysis of PARADIGM-HF and PARAGON-HF

Doctor H. Lu (Lausanne, CH)

Abstract Slides Video

Presentation thumbnail

Tafamidis treatment for transthyretin amyloid cardiomyopathy: results from an open-label, early-access, long-term study extension in an all-comers population

Professor M. Crespo-Leiro (A Coruna, ES)

Abstract Slides Video

Presentation thumbnail

Efficacy of sotagliflozin by diabetes duration: a secondary analysis of SCORED

Doctor R. Aggarwal (Boston, US)

Abstract Slides Video

Presentation thumbnail

Effects of dapagliflozin in heart failure according to duration of type 2 diabetes: a patient-level meta-analysis of DAPA-HF and DELIVER

Doctor J. Butt (Copenhagen, DK)

Abstract Slides Video

Presentation thumbnail

Long-term follow-up of the TRED-HF trial

Miss L. Cheng (London, GB)

Abstract Slides Video

Access the full session

Session thumbnail

Drug therapy for heart failure: what is new?

The Event

Event poster

ESC Congress 2024

30 August 2024 12:00 CET

You may be interested in

Congress Presentation

Amyloid-specific medication in transthyretin amyloid cardiomyopathy: a systemic review and meta-analysis.

Congress Presentation

Transthyretin stabiliser therapy in patients with transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis

Congress Presentation

Effects of targeted transthyretin amyloid cardiomyopathy treatments on clinical outcomes a meta-analysis

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources